专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010068923A3 AGENTS THAT SELECTIVELY INHIBIT CD25 ON DENDRITIC CELLS OR T CELLS AND THEIR USE 审中-公开
标题翻译：选择性抑制CD25对细胞或细胞的作用及其使用
公开(公告)号：WO2010068923A3
公开(公告)日：2010-12-02
申请号：PCT/US2009067755
申请日：2009-12-11
申请人： US HEALTH , BIELEKOVA BIBIANA , EDWAN JEHAD , MARTIN JAYNE
发明人： BIELEKOVA BIBIANA , EDWAN JEHAD , MARTIN JAYNE
IPC分类号： A61K39/395 , A61P35/00 , C07K16/18 , C12N5/0784
CPC分类号： C07K16/2866 , A61K2039/505 , C07K2317/24 , C07K2317/73 , C07K2317/76
摘要： Agent that selectively inhibit CD25 on dendritic cells on T cells are disclosed herein. Methods are provided for treating a subject with an immune mediated disease. These methods include administering to the subject a therapeutically effective amount of an agent that selectively inhibits CD25 on dendritic cells, thereby treating the immune mediated disorder in the subject. In other embodiments, methods are provided for treating a subject with a tumor. The methods include administering to the subject a therapeutically effective amount of an agent that selectively inhibits CD25 on T cells, thereby treating the tumor in the subject. Compositions are disclosed that include a composite molecule and a carrier, wherein the composite molecule comprises an agent that selectively binds dendritic cells or an agent that selectively binds T cells, wherein the agent is covalently bound to a CD25 antagonist. Methods for selecting an agent of use in treating an immune mediated disorder are also disclosed.
摘要翻译：本文公开了在T细胞上树突状细胞上选择性抑制CD25的药剂。提供了用免疫介导的疾病治疗受试者的方法。这些方法包括向受试者施用治疗有效量的选择性抑制树突状细胞上的CD25的试剂，从而治疗受试者的免疫介导的病症。在其它实施方案中，提供了用于用肿瘤治疗受试者的方法。所述方法包括向受试者施用治疗有效量的选择性抑制T细胞上的CD25的药剂，从而治疗受试者的肿瘤。公开了包含复合分子和载体的组合物，其中所述复合分子包含选择性结合树突状细胞的试剂或选择性结合T细胞的试剂，其中所述试剂与CD25拮抗剂共价结合。还公开了用于选择用于治疗免疫介导的病症的药剂的方法。

2. 发明申请

WO2010068923A2 AGENTS THAT SELECTIVELY INHIBIT CD25 ON DENDRITIC CELLS OR T CELLS AND THEIR USE 审中-公开
标题翻译：在树突状细胞或T细胞上选择性抑制CD25的药剂及其使用
公开(公告)号：WO2010068923A2
公开(公告)日：2010-06-17
申请号：PCT/US2009/067755
申请日：2009-12-11
申请人： THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES , BIELEKOVA, Bibiana , EDWAN, Jehad , MARTIN, Jayne
发明人： BIELEKOVA, Bibiana , EDWAN, Jehad , MARTIN, Jayne
IPC分类号： A61K39/395 , A61P35/00 , C07K16/18 , C12N5/0784
CPC分类号： C07K16/2866 , A61K2039/505 , C07K2317/24 , C07K2317/73 , C07K2317/76
摘要： Agent that selectively inhibit CD25 on dendritic cells on T cells are disclosed herein. Methods are provided for treating a subject with an immune mediated disease. These methods include administering to the subject a therapeutically effective amount of an agent that selectively inhibits CD25 on dendritic cells, thereby treating the immune mediated disorder in the subject. In other embodiments, methods are provided for treating a subject with a tumor. The methods include administering to the subject a therapeutically effective amount of an agent that selectively inhibits CD25 on T cells, thereby treating the tumor in the subject. Compositions are disclosed that include a composite molecule and a carrier, wherein the composite molecule comprises an agent that selectively binds dendritic cells or an agent that selectively binds T cells, wherein the agent is covalently bound to a CD25 antagonist. Methods for selecting an agent of use in treating an immune mediated disorder are also disclosed.
摘要翻译：本文公开了选择性抑制T细胞上的树突细胞上的CD25的药剂。提供了用于治疗患有免疫介导的疾病的受试者的方法。这些方法包括向受试者施用治疗有效量的选择性抑制树突细胞上CD25的试剂，由此治疗受试者中免疫介导的病症。在其他实施方案中，提供了用于治疗患有肿瘤的受试者的方法。该方法包括向受试者施用治疗有效量的选择性抑制T细胞上CD25的试剂，由此治疗受试者中的肿瘤。公开了包含复合分子和载体的组合物，其中所述复合分子包含选择性结合树突细胞的试剂或选择性结合T细胞的试剂，其中所述试剂与CD25拮抗剂共价结合。还公开了用于选择治疗免疫介导的病症的药剂的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式